Evidence map›Paper›PMID 36253968›Full record

ArticleThe American journal of clinical nutrition2022

Associations of erythrocyte omega-3 fatty acids with cognition, brain imaging and biomarkers in the Alzheimer's disease neuroimaging initiative: cross-sectional and longitudinal retrospective analyses.

Laure Rouch, Kelly Virecoulon Giudici, Christelle Cantet, Sophie Guyonnet, Julien Delrieu, Philippe Legrand, Daniel Catheline, Sandrine Andrieu, Michael Weiner, Philipe de Souto Barreto and 2 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in The American journal of clinical nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00106899 (Alzheimer's Disease Neuroimaging Initiative), which is not on this map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00106899 completednot on this map

Alzheimer's Disease Neuroimaging Initiative

TypeobservationalSponsorAlzheimer's Disease Cooperative Study (ADCS)Ran2005 to 2011Enrolled818ConditionsAlzheimer's DiseaseArmsMagnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Lumbar Puncture (LP)
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Effects of APOE4 on omega-3 brain metabolism across the lifespan.Trends in endocrinology and metabolism: TEM · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. The omega-3 index in Alzheimer's disease: Ready for prime time?The American journal of clinical nutrition · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Laure RouchGerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital, Toulouse, Franc.ORCID 0000-0001-5992-1128
Kelly Virecoulon GiudiciGerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital, Toulouse, Franc.
Christelle CantetGerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital, Toulouse, Franc.
Sophie GuyonnetGerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital, Toulouse, Franc.
Julien DelrieuGerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital, Toulouse, Franc.
Philippe LegrandLaboratory of Biochemistry and Human Nutrition, Institut Agro, Institut National de la Santé et de la Recherche Médicale 1241, Rennes, France.
Daniel CathelineLaboratory of Biochemistry and Human Nutrition, Institut Agro, Institut National de la Santé et de la Recherche Médicale 1241, Rennes, France.
Sandrine AndrieuCERPOP Centre d'Epidémiologie et de Recherche en Santé des Populations, Institut National de la Santé et de la Recherche Médicale 1295, University of Toulouse, Toulouse, France.
Michael WeinerDepartment of Veterans Affairs Medical Center, San Francisco, CA, USA.
Philipe de Souto BarretoGerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital, Toulouse, Franc.
Bruno VellasGerontopole of Toulouse, Institute of Ageing, Toulouse University Hospital, Toulouse, Franc.
Alzheimer's Disease Neuroimaging Initiative
Institut de Mathématiques de Toulouse · FRUnité de Nutrition Humaine · FRSan Francisco VA Medical Center · USUniversité Fédérale de Toulouse Midi-Pyrénées · FRUniversité Toulouse III - Paul Sabatier · FR

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
NIA NIH HHS U01 AG024904NIH HHS U01 AG024904
6 · The paper itself

Abstract

backgroundThe association between omega-3 (ω-3) PUFAs and cognition, brain imaging and biomarkers is still not fully established.

objectivesThe aim was to analyze the cross-sectional and retrospective longitudinal associations between erythrocyte ω-3 index and cognition, brain imaging, and biomarkers among older adults.

methodsA total of 832 Alzheimer's Disease Neuroimaging Initiative 3 (ADNI-3) participants, with a mean (SD) age of 74.0 (7.9) y, 50.8% female, 55.9% cognitively normal, 32.7% with mild cognitive impairment, and 11.4% with Alzheimer disease (AD) were included. A low ω-3 index (%EPA + %DHA) was defined as the lowest quartile (≤3.70%). Cognitive tests [composite score, AD Assessment Scale Cognitive (ADAS-Cog), Wechsler Memory Scale (WMS), Trail Making Test, Category Fluency, Mini-Mental State Examination, Montreal Cognitive Assessment] and brain variables [hippocampal volume, white matter hyperintensities (WMHs), positron emission tomography (PET) amyloid-β (Aβ) and tau] were considered as outcomes in regression models.

resultsLow ω-3 index was not associated with cognition, hippocampal, and WMH volume or brain Aβ and tau after adjustment for demographics, ApoEε4, cardiovascular disease, BMI, and total intracranial volume in the cross-sectional analysis. In the retrospective analysis, low ω-3 index was associated with greater Aβ accumulation (adjusted β = 0.02; 95% CI: 0.01, 0.03; P = 0.003). The composite cognitive score did not differ between groups; however, low ω-3 index was significantly associated with greater WMS-delayed recall cognitive decline (adjusted β = -1.18; 95% CI: -2.16, -0.19; P = 0.019), but unexpectedly lower total ADAS-Cog cognitive decline. Low ω-3 index was cross-sectionally associated with lower WMS performance (adjusted β = -1.81, SE = 0.73, P = 0.014) and higher tau accumulation among ApoE ε4 carriers.

conclusionsLongitudinally, low ω-3 index was associated with greater Aβ accumulation and WMS cognitive decline but unexpectedly with lower total ADAS-Cog cognitive decline. Although no associations were cross-sectionally found in the whole population, low ω-3 index was associated with lower WMS cognition and higher tau accumulation among ApoE ε4 carriers. The Alzheimer's Disease Neuroimaging Initiative (ADNI) is registered at clinicaltrials.gov as NCT00106899.

Indexed as

Alzheimer DiseaseCognitive DysfunctionFatty Acids, Omega-3AgedAmyloid beta-PeptidesApolipoprotein E4BiomarkersBrainCognitionCross-Sectional StudiesErythrocytesFemaleHumansMaleNeuroimagingPositron-Emission TomographyAmyloid beta-PeptidesApolipoprotein E4BiomarkersFatty Acids, Omega-3Alzheimer diseasebiomarkersbrain imagingcognitiondocosahexaenoic acideicosapentaenoic acidmild cognitive impairmentomega-3

Identifiers

PMID36253968
PMCPMC9761759
OpenAlexW4306673754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.